Obesity Author: George A. Bray, MD
Editorial changes - 2009-11-18
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Quality Measures Quality Measures
Glossary
ACE
angiotensin-converting enzyme
BMI
body mass index
CDC
Centers for Disease Control and Prevention
CI
confidence interval
CNS
central nervous system
CT
computed tomography
DASH
Dietary Approaches to Stop Hypertension
DNA
deoxyribonucleic acid
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GTT
glucose tolerance test
HDL
high-density lipoprotein
ICU
intensive care unit
LDL
low-density lipoprotein
LH
luteinizing hormone
MRI
magnetic resonance imaging
NCEP
National Cholesterol Education Program; Adult Panel III (ATP III)
OR
odds ratio
OTC
over the counter
SHBG
sex hormone-binding globulin
tid
three times daily
TSH
thyrotropin stimulating hormone
WHR
waist-to-hip ratio
George A. Bray, MD, is a speaker for Eli Lilly, Amylin Corp., and Merck & Co., received grants from Merck & Co., and Takeda Pharmaceuticals; and has consulted for Sanofi-Aventis, Merck, and Amylin.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.